We are discovering and developing novel antiviral compounds to treat viral infections including Coronavirus and Influenza Virus infections by leveraging our proprietary drug discovery platform.

We are leveraging our core competencies and decade of experience in antiviral therapeutics to combat the global COVID-19 health crisis. Our COVID-19 program consists of work performed by our contract research organization partners around the world and in our own laboratory. Given the growing global need for a treatment, we are advancing preclinical development of antiviral therapeutics targeting SARS-CoV-2 as quickly and efficiently as possible, while advancing the discovery and development of antiviral compounds for other high-value indications.

Targeted Solutions for Viral Diseases

Novel antiviral therapeutics for the treatment of serious and/or chronic viral diseases including influenza, COVID-19, hepatitis C and gastroenteritis caused by norovirus.

View Product Pipeline

About Us

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza virus, SARS-CoV-2 virus, hepatitis C virus, and norovirus.

Learn More

Technology

We utilize unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs.

Learn More

Development Programs

Our development programs include a wide variety of serious and/or chronic viral diseases including influenza, COVID-19, hepatitis C and gastroenteritis caused by norovirus.

Learn More
Program Discovery Preclinical Phase 1 Phase 2a Phase 3
Hepatitis C CC-31244 - University of MD
(Pan-genotypic NS5B NNI)
Discovery Phase complete
Preclinical Phase complete
Phase 1 Phase complete
Phase 2a Phase in progress
Phase 3 Phase not started
Influenza CC-42344
(Influenza A PB2 Inhibitor)
Discovery Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2a Phase not started
Phase 3 Phase not started
Influenza Influenza A/B Inhibitor
Discovery Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2a Phase not started
Phase 3 Phase not started
Coronavirus (COVID-19) Replication and Protease Inhibitor
Discovery Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2a Phase not started
Phase 3 Phase not started
Norovirus (Gastroenteritis) Replication and Protease Inhibitor
Discovery Phase complete
Preclinical Phase in progress
Phase 1 Phase not started
Phase 2a Phase not started
Phase 3 Phase not started

Investor Presentation

View our latest Corporate Presentation

View Presentation View Fact Sheet

Corporate Overview

Gary Wilcox, Ph.D., Chairman and CEO provides background on the Company's innovative platform and highlights upcoming program milestones.